endpts.com·May 6, 2026
CellCentric has secured $220 million in funding to advance the development of a new pill for multiple myeloma patients who have run out of treatment options. This investment aims to bring the innovative therapy to market and address the needs of this patient population.
CellCentric's recent $220 million funding round to advance their multiple myeloma pill, aimed at patients who have exhausted other treatment options, indicates a significant investment opportunity in the niche market of addressing unmet needs in cancer treatment. This funding can be a signal for investors to watch for emerging therapies that target specific patient populations, especially those with limited alternatives.